公司資料
Precision BioSciences 股價、新聞與催化劑
- 股票代碼:
- DTIL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.40 USD (-0.40%)
收盤價
最後更新: 2026年8月17日
163M USD
市值
股價為何變動
As of Aug 17, 2026, DTIL closed down 0.40% at $7.40. No new same-company headline was identified in the current news window.
公司概覽
ARCUS Gene Editing Platform
Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material.
PBGENE-HBV
PBGENE-HBV is a wholly owned in vivo editing therapy in the Phase 1/2a ELIMINATE-B trial for chronic hepatitis B. It is designed to eliminate covalently closed circular DNA, the source of infectious viral replication, while inactivating integrated HBV DNA.
PBGENE-DMD
PBGENE-DMD uses two ARCUS nucleases delivered in one AAV to excise exons 45 through 55 of the dystrophin gene. The approach is intended to restore a near-full-length functional dystrophin protein in a large subset of patients with Duchenne muscular dystrophy and is entering the Phase 1/2 FUNCTION-DMD trial.
Partnered In Vivo Programs
iECURE is developing ECUR-506, an ARCUS-mediated gene-insertion therapy for neonatal-onset ornithine transcarbamylase deficiency. The OTC-HOPE study is evaluating whether targeted insertion can produce durable metabolic correction.
Partnered Cell Therapy
The allogeneic CAR-T candidate azer-cel is licensed to partners for development in lymphoma, progressive multiple sclerosis and other autoimmune diseases. These programs provide external validation and potential economics from an earlier ex vivo application of ARCUS technology.
未來催化劑
- PBGENE-HBV clinical data at the EASL Congress on May 27–30, 2026, with further updates at hepatitis meetings during 2026.
- Initial patient screening at new ELIMINATE-B sites in France and Romania expected in the second quarter of 2026.
- First patient dosing and continued site expansion in the Phase 1/2 FUNCTION-DMD trial.
- ECUR-506 clinical updates at ASGCT and SIMD in May 2026.
- Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。